DSGN Stock — Design Therapeutics Inc.: Cash, EV, Pipeline

What they do

Our GeneTAC ® small molecules are designed to selectively target expanded genetic repeat sequences, modulate gene expression either by dialing up or down mRNA transcription, depending on the cause of the disease, and restore cellular health. As a platform, we believe that GeneTAC ® molecules have broad potential applicability across currently unaddressed degenerative, monogenic nucleotide repeat expansion diseases affecting millions of individuals worldwide.

Source: 10-K FY2025 via SEC EDGAR

Share price

$10.21

Market cap

$653.8M

Cash

$208.6M

Enterprise value

$445.2M

Balance sheet

Cash	$208.6M
Debt	$0.0M
Net cash	$208.6M
Enterprise value	$445.2M
Basic shares	64.0M shares
Fully diluted shares	82.7M shares
Fully diluted market cap	$844.9M
Cash per share	$3.26
Quarterly burn	$15.5M
Cash runway	13.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

62.6M

Pre-funded warrants

0.0M

Options

17.4M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.8M

FDSO

82.7M

Cap table as of 2026-06-30.

Price history

Loading DSGN daily closes…

Loading price history…

Next catalyst

DT-168 · Now - Nov 24, 2026 Now · Phase 2 · Fuchs Endothelial Corneal Dystrophy; Fuchs

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 24, 2026 Now	DT-168	Phase 2	Fuchs Endothelial Corneal Dystrophy; Fuchs	—
Jan 12 - Feb 23 in 9 wks	DT-216P2	Phase 2	Friedreich Ataxia	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	DT-168 Phase 2 biomarker trial in FECD	Phase 2	FECD	2027
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	DT-818 Phase 1 MAD trial in myotonic dystrophy type 1	Phase 1	myotonic dystrophy type 1	2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

DT-216P2

Phase 1 · Active Modality: small-molecule gene-targeted chimera (GeneTAC)

Aliases DT-216

Target FXN (frataxin)

Indications

Friedreich ataxia (FA) (Phase 1)

Status note Lead program. Improved formulation of DT-216 enabling more sustained exposure; Phase 1 SAD in healthy volunteers via IV and subcutaneous routes generally well-tolerated.

DT-168

Phase 2 · Active Modality: small-molecule gene-targeted chimera (GeneTAC), ophthalmic solution (eye drop)

Target TCF4 (mutant, expanded CTG repeat)

Indications

Fuchs endothelial corneal dystrophy (FECD) (Phase 2)

Catalysts

— 2027

Status note Phase 2 data now expected 2027 due to delay in anticipated supply of blow-fill-seal eye droppers.

DT-818

Phase 1 · Active Modality: small-molecule gene-targeted chimera (GeneTAC)

Target DMPK (mutant, expanded CTG repeat)

Indications

Myotonic dystrophy type-1 (DM1) (Phase 1)

Catalysts

— 2027

Status note Development candidate declared Q4 2025; dosing of DM1 patients in open-label Phase 1 MAD trial initiated in first half of 2026.

HD GeneTAC program (candidate not yet declared)

Discovery · Active Modality: small-molecule gene-targeted chimera (GeneTAC)

Target HTT (expanded repeat)

Indications

Huntington's disease (HD) (Discovery)

Status note Early-stage research program; additional product candidates to be declared as they progress.

Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	DT-216P2
Lead indication	Friedreich Ataxia
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06874010	Phase 2	Recruiting	Sponsor	DSGN	—	Friedreich Ataxia	Q1 2027 Est. Feb 14, 2027 · quarter midpoint
NCT07024693	Phase 2	Recruiting	Sponsor	DSGN	—	Fuchs Endothelial Corneal Dystrophy; Fuchs	—
NCT06772870	Phase 1	Not yet recruiting	Sponsor	DSGN	—	Friedreich Ataxia	Q1 2027 Est. Feb 14, 2027 · quarter midpoint

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Design Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	3,000,000	+1,050,000	1.87%	2026-08-14
Baker Bros. Advisors	2,678,430	+92,452	0.19%	2026-08-14
Frazier Life Sciences	1,809,854	+1,809,854	0.57%	2026-08-14
Vivo Capital	1,612,903	no change	2.13%	2026-08-14
DAFNA Capital	102,600	+102,600	0.28%	2026-08-14
ADAR1 Capital Management	0	-10,000	0.00%	2026-08-14
RA Capital Management	0	-2,972,973	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

DSGN — Design Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

DSGN — Design Therapeutics Inc.